BioMarin Announces Second Quarter 2020 Total Revenue Growth of 11% to $430 million
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/9/2026
- After-Hours Movers: COO, AEO, NAVN, AVAV, TORO
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
BioMarin Pharmaceutical Inc. (BMRN) PT Raised to $108 at BMO Capital
August 5, 2020 9:46 AM EDTBMO Capital analyst George Farmer raised the price target on BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) to $108.00 (from $94.00) while maintaining a Market Perform rating.
The analyst commented, "Following model adjustments, we increase our PT to $108 from $94 and maintain our Market Perform rating ahead... More
BioMarin Pharma (BMRN) Misses Q2 EPS by 5c, Revenue Beats
August 4, 2020 4:16 PM EDTBioMarin Pharma (NASDAQ: BMRN) reported Q2 EPS of ($0.16), $0.05 worse than the analyst estimate of ($0.11). Revenue for the quarter came in at $430 million versus the consensus estimate of $418.61 million.
GUIDANCE:
BioMarin Pharma sees 2020 revenue of $1.85-1.95 billion, versus the consensus of $1.9... More
